LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 813

Search options

  1. Article: [No title information]

    Scheen, A J

    Revue medicale de Liege

    2023  Volume 78, Issue 1, Page(s) 1–3

    Title translation Éditorial. Le système des soins de santé ébranlé par les crises.
    MeSH term(s) Humans ; Delivery of Health Care
    Language French
    Publishing date 2023-01-12
    Publishing country Belgium
    Document type Editorial
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Vignette thérapeutique de l’étudiant. Prescrire un inhibiteur des SGLT2 pour une insuffisance cardiaque sans risquer une hypoglycémie.

    Scheen, A J

    Revue medicale de Liege

    2022  Volume 77, Issue 11, Page(s) 684–688

    Abstract: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i or gliflozins) improve the prognosis of patients with heart failure, independently of the presence of diabetes. They are now recommended for the treatment of heart failure in international guidelines. ...

    Title translation Prescribing a SGLT2 inhibitor for treating heart failure without inducing hypoglycaemia.
    Abstract Sodium-glucose cotransporter type 2 inhibitors (SGLT2i or gliflozins) improve the prognosis of patients with heart failure, independently of the presence of diabetes. They are now recommended for the treatment of heart failure in international guidelines. The addition of a gliflozin driven by such a cardiological indication may require some adjustment of the antidiabetic therapy. The aim of this concise article is to discuss the potential risk of hypoglycaemia, highly deleterious in fragile patients at risk, following the prescription of a gliflozin in patients with heart failure. Different clinical situations will be considered, both in nondiabetic patients and in patients with type 2 diabetes already treated with a variety of antihyperglycaemic agents, metformin, sulphonylureas, gliptins, GLP-1 receptor agonists and insulin.
    MeSH term(s) Humans ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/adverse effects ; Hypoglycemia/chemically induced ; Heart Failure/drug therapy
    Chemical Substances Sodium-Glucose Transporter 2 Inhibitors ; Hypoglycemic Agents
    Language French
    Publishing date 2022-10-20
    Publishing country Belgium
    Document type English Abstract ; Practice Guideline
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Editorial. L’eau et le feu.

    Scheen, A J

    Revue medicale de Liege

    2022  Volume 77, Issue 1, Page(s) 1–4

    Title translation Editorial. Fire and Water.
    Language French
    Publishing date 2022-01-14
    Publishing country Belgium
    Document type Editorial
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Les médicaments anti-inflammatoires : des anciens classiques aux biothérapies et inhibiteurs de JAK.

    Scheen, A J

    Revue medicale de Liege

    2022  Volume 77, Issue 5-6, Page(s) 399–409

    Abstract: Anti-inflammatory medications are known since a long time and still remain among the most used drugs in clinical practice. They belong to a variety of pharmacological classes and act via very different biochemical mechanisms. Nonsteroid anti-inflammatory ...

    Title translation Anti-inflammatory drugs : from old classical ones to biotherapies and JAK inhibitors.
    Abstract Anti-inflammatory medications are known since a long time and still remain among the most used drugs in clinical practice. They belong to a variety of pharmacological classes and act via very different biochemical mechanisms. Nonsteroid anti-inflammatory drugs, which are derived from acetylsalicylic acid, and cortisone with its multiple derivative molecules (glucocorticoids) remain the background therapy of diseases associated with inflammation, either acute or chronic. Some old molecules, known to exert an anti-inflammatory activity, still have specific indications, colchicine and methotrexate as examples. However, the greatest innovation of the last two decades results from the launch of biological therapies, starting with the use of anti-TNF? agents to move towards monoclonal antibodies targeting various pro-inflammatory interleukins (IL-1, IL-6, IL-5, IL-17, IL-23, …). Finally, small molecules acting as JANUS kinase inhibitors or tyrosine kinase 2 inhibitors open new alternatives in severe diseases that are resistant to other anti-inflammatory drugs. The interest for anti-inflammatory medications has been reinforced since the COVID-19 outbreak.
    MeSH term(s) Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Biological Therapy ; COVID-19/drug therapy ; Humans ; Janus Kinase Inhibitors/pharmacology ; Janus Kinase Inhibitors/therapeutic use ; Tumor Necrosis Factor Inhibitors
    Chemical Substances Anti-Inflammatory Agents ; Janus Kinase Inhibitors ; Tumor Necrosis Factor Inhibitors
    Language French
    Publishing date 2022-06-03
    Publishing country Belgium
    Document type Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: À propos de la sécurité d’emploi des inhibiteurs des SGLT2 (gliflozines).

    Scheen, A J

    Revue medicale de Liege

    2021  Volume 77, Issue 4, Page(s) 218–223

    Abstract: Since their launch, sodium-glucose cotransporter type 2 inhibitors (SGLT2is) were suspected to be associated with various adverse events. They contributed to delay, as in France, or to restrict the use of this new pharmacological class in clinical ... ...

    Title translation About the safety profile of SGLT2 inhibitors.
    Abstract Since their launch, sodium-glucose cotransporter type 2 inhibitors (SGLT2is) were suspected to be associated with various adverse events. They contributed to delay, as in France, or to restrict the use of this new pharmacological class in clinical practice, despite remarkable results reported in large cardiovascular or renal clinical trials. This article is devoted to three major adverse events that were imputed to SGLT2is : lower-limb extremity amputations, euglycaemic ketoacidosis and acute kidney injuries. In contrast to pharmacovigilance reports that raised suspicion, analysis of all data from the literature, either placebo-controlled trials or retrospective observational cohort studies, led to rather reassuring conclusions. The incidence of amputations does not appear to be increased while cases of acute kidney injury are reduced instead of increased as suspected earlier. Ketoacidosis events are almost doubled with SGLT2is versus comparators, yet their incidence remains extremely low among patients with type 2 diabetes. Of note, this potentially severe complication contributes to the denial of marketing authorization and reimbursement of SGLT2is in the population with type 1 diabetes.
    MeSH term(s) Acute Kidney Injury/chemically induced ; Acute Kidney Injury/epidemiology ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents/adverse effects ; Ketosis/chemically induced ; Ketosis/complications ; Ketosis/drug therapy ; Retrospective Studies ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects
    Chemical Substances Hypoglycemic Agents ; Sodium-Glucose Transporter 2 Inhibitors
    Language French
    Publishing date 2021-12-08
    Publishing country Belgium
    Document type Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Comment je traite… Quelle place encore réserver aux sulfamides hypoglycémiants et avec quelles précautions ?

    Scheen, A J

    Revue medicale de Liege

    2021  Volume 76, Issue 1, Page(s) 7–12

    Abstract: Sulphonylureas (SU) for a long time occupied an essential role in the management of type 2 diabetes (T2D). However, the launch of new oral antidiabetic drugs (OAD), firstly DPP-4 inhibitors (gliptins) and more recently SGLT2 inhibitors (gliflozins), has ... ...

    Title translation Which place to be reserved to sulphonylureas and which precautions to be taken ?
    Abstract Sulphonylureas (SU) for a long time occupied an essential role in the management of type 2 diabetes (T2D). However, the launch of new oral antidiabetic drugs (OAD), firstly DPP-4 inhibitors (gliptins) and more recently SGLT2 inhibitors (gliflozins), has markedly changed the scene. Indeed, in contrast to SU, these new OAD (of course more expensive) offer the advantage of a very low risk of hypoglycaemia and a beneficial impact on bodyweight. Furthermore, gliflozins have proven to exert a cardiovascular and renal protection in patients at high risk. SU keep a place in the management of T2D, yet it becomes more and more limited. For sure, SU should be avoided among elderly frailty people and patients at high risk of hypoglycaemia.
    MeSH term(s) Aged ; Diabetes Mellitus, Type 2/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use ; Humans ; Hypoglycemic Agents/adverse effects ; Sodium-Glucose Transporter 2 Inhibitors ; Sulfonylurea Compounds
    Chemical Substances Dipeptidyl-Peptidase IV Inhibitors ; Hypoglycemic Agents ; Sodium-Glucose Transporter 2 Inhibitors ; Sulfonylurea Compounds
    Language French
    Publishing date 2021-01-14
    Publishing country Belgium
    Document type Practice Guideline
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Environnement et cancer : pas facile de disséquer l’exposome !

    Scheen, A J

    Revue medicale de Liege

    2021  Volume 76, Issue 5-6, Page(s) 337–343

    Abstract: Environment contains numerous potentially toxic substances among which certain have demonstrated to be carcinogenic. They can reach the human organism mainly through the repiratory or digestive routes. Even if it is not always easy to demonstrate a ... ...

    Title translation Environment and cancer : not easy to dissect the exposome !
    Abstract Environment contains numerous potentially toxic substances among which certain have demonstrated to be carcinogenic. They can reach the human organism mainly through the repiratory or digestive routes. Even if it is not always easy to demonstrate a causal relationship in observational studies whose interpretation is limited by numerous confounding factors, some compounds from the environment are clearly associated with a higher risk of cancers. The present article describes the effects of both outdoor and indoor air pollution, pesticides, some endocrine disruptors and radiations. The identification of environmental factors associated with a higher risk of cancer allows implement eradication strategies and thereby efficacious prevention.
    MeSH term(s) Air Pollution, Indoor ; Exposome ; Humans ; Neoplasms/epidemiology ; Neoplasms/etiology
    Language French
    Publishing date 2021-06-03
    Publishing country Belgium
    Document type Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Editorial SARS-CoV-2 et COVID-19 : pas au bout des doutes, questionnements et controverses.

    Scheen, A J

    Revue medicale de Liege

    2020  Volume 75, Issue S1, Page(s) 1–5

    Title translation SARS-CoV-2 and COVID-19: not at the end of doubts, questions and controversies.
    Language French
    Publishing date 2020-11-19
    Publishing country Belgium
    Document type Editorial ; Comment
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Editorial. Avancées thérapeutiques au cours de la décennie 2010-2020.

    Scheen, A J

    Revue medicale de Liege

    2020  Volume 75, Issue 5-6, Page(s) 273–275

    Title translation Editorial. Therapeutic advances during the decade 2010-2020.
    MeSH term(s) Biomedical Research ; Humans
    Language French
    Publishing date 2020-07-09
    Publishing country Belgium
    Document type Editorial
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Le médicament du mois. Ertugliflozine seule et en combinaisons fixes : «la passe de trois» pour ce nouvel inhibiteur des SGLT2.

    Scheen, A J

    Revue medicale de Liege

    2020  Volume 75, Issue 9, Page(s) 626–632

    Abstract: Ertugliflozin is a new sodium-glucose cotransporter type 2 inhibitor (SGLT2i) that is indicated in the treatment of type 2 diabetes. It has been investigated in the large phase 3 development programme VERTIS, in monotherapy and in association with ... ...

    Title translation Ertugliflozin alone and in fixed-dose combinations : «pass of three».
    Abstract Ertugliflozin is a new sodium-glucose cotransporter type 2 inhibitor (SGLT2i) that is indicated in the treatment of type 2 diabetes. It has been investigated in the large phase 3 development programme VERTIS, in monotherapy and in association with different antidiabetic medications, including insulin. The add-on of ertugliflozin to metformin (VERTIS MET) and the association ertugliflozin-sitagliptin (VERTIS-SITA, VERTIS FACTORIAL, VERTIS SITA2) showed a significant reduction in glycated haemoglobin, without hypoglycaemia, together with a diminution of body weight and arterial blood pressure. As expected, more genital mycotic infections were observed, the only adverse event consistently reported. The cardiovascular safety of ertugliflozin has been demonstrated in VERTIS CV. Ertugliflozin is commercialized with two doses 5 mg and 15 mg. This SGLT2i is also available in fixed-dose combinations, ertugliflozin-metformin and ertugliflozin-sitagliptin. The three presentations offer a greater flexibility to the practitioner to optimize therapeutic choices for a complex disease where the treatment should be individualized according to the patient profile.
    MeSH term(s) Bridged Bicyclo Compounds, Heterocyclic ; Diabetes Mellitus, Type 2 ; Humans ; Hypoglycemic Agents ; Metformin
    Chemical Substances Bridged Bicyclo Compounds, Heterocyclic ; Hypoglycemic Agents ; ertugliflozin (6C282481IP) ; Metformin (9100L32L2N)
    Language French
    Publishing date 2020-09-09
    Publishing country Belgium
    Document type Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top